A new classification of prodrugs: Regulatory perspectives

Pharmaceuticals

Volumn 2, Issue 3, 2009, Pages 77-81

  Wu, Kuei Meng ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug development; Prodrug; Prodrug classification

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CAPTOPRIL; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CARISOPRODOL; CYCLOPHOSPHAMIDE; DIAMORPHINE; ETOPOFOS; FLUOROURACIL; FOSAMPRENAVIR; FOSFESTROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVODOPA; MERCAPTOPURINE; MITOMYCIN C; MOLSIDOMINE; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; PALIPERIDONE; PHENACETIN; PRIMIDONE; PRODRUG; PSILOCYBINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; VALGANCICLOVIR; ZIDOVUDINE;

ARTICLE; BODY FLUID; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG NOMENCLATURE; DRUG SAFETY; EXTRACELLULAR FLUID; HUMAN; INTESTINE FLUID; LIVER; LUNG; RISK ASSESSMENT; SYSTEMIC CIRCULATION; TARGET CELL;

EID: 74549117722     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph2030077     Document Type: Article

References (7)

1. Brunton, L.; Lazo, J.; Parker, K. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th ed.; McGraw-Hill: New York, NY, USA, 2005.
2. Goldstein A.; Aronow, L.; S. Kalman, S. Principles of Drug Action, 2nd ed.; John Wiley & Sons: Hoboken, NJ, USA, 1974.
3. Han, H.K.; Amidon, G.L. Targeted prodrug design to optimize drug delivery. AAPS Pharm. Sci. 2000, 2, 1-11.
4. Hu, L. The prodrug approach to better targeting. In Meeting Report of Prodrugs: Effective Solutions for Solubility, Permeability, and Targeting Challenges, 28-29 June 2004, Philadelphia, PA, USA; www.currentdrugdiscovery. com, accessed on 8 August 2009.
5. Liederer, B.M.; Borchardt, R.T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 2006, 95, 1177-1195.
6. Wu, K.M.; Farrelly, J. Regulatory perspectives of type II prodrug development: preclinical pharm/tox analysis and the role of comparative toxicology. FDA Sci. Forum 2006, 1:134.
7. Wu, K.M.; Farrelly, J. Regulatory perspectives of type II prodrug development and time-dependent toxicity management: Nonclinical pharm/tox analysis and the role of comparative toxicology. Toxicology 2007, 236, 1-6.